Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long Term Follow up Safety Study of Patients in the AVXS-101-CL-101 Gene Replacement Therapy Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS 101

NCT03421977 is registered in ClinicalTrials.gov with Novartis Gene Therapies as lead sponsor.

NCT NCT03421977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03421977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long Term Follow up Safety Study of Patients in the AVXS-101-CL-101 Gene Replacement Therapy Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS 101
Lead sponsor
Novartis Gene Therapies
Phase
Observational
Overall status
Active, not recruiting
Start date
September 21, 2017
Completion date
December 2, 2030
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

spinal muscular atrophy 1